Richard Peters Merrimack Pharmaceuticals CEO Rating

Merrimack Pharmaceuticals CEO Richard Peters Bio

Dr. Richard Peters, M.D., Ph.D. has been the Chief Executive Officer and President of Merrimack Pharmaceuticals, Inc. since February 6, 2017 and served as its Principal Financial Officer from June 2017 to August 21, 2017. Dr. Peters is a Harvard-trained physician-scientist. He has over 20 years of biotech (oncology and specialty care) experience including roles of increasing responsibility in medical affairs at Onyx Pharmaceuticals, Inc. and Amgen Inc. He served as Global Head of Rare Diseases and Senior Vice President at Genzyme Corporation (Sanofi Genzyme) from January 2015 to February 6, 2017 and served as its Vice President. He was responsible for a global, $3 billion per year business with 10 commercialized products and a robust, multi-product development pipeline focusing on several therapeutic areas. He joined Genzyme in 2008. He oversaw a portfolio of products that serves patients in more than 90 countries worldwide. He was a co-founder of Mednav, Inc. and served as its Chief Executive Officer. Dr. Peters served in various capacities at Sanofi Genzyme, a global pharmaceutical company, since 2008, including as Senior Vice President, Head of Global Rare Diseases Business Unit since January 2015, Vice President, Strategy Development Officer, U.S. Rare Disease Unit from May 2014 to December 2014, Vice President, Division Medical Officer, Global Oncology Division from 2011 to May 2014 and Vice President, Head of Global and U.S. Medical Affairs, Hematology and Transplant from 2008 to 2011. He served as Deputy Head for the Genzyme Global Rare Diseases Division at Genzyme Therapeutic Products Limited Partnership. He served as Senior Director of Medical Affairs at Onyx Pharmaceuticals. He served as Director of Medical Affairs at Amgen Inc. He has been a Director of Merrimack Pharmaceuticals, Inc. since February 6, 2017. He serves as Scientific and Clinical Advisor at Aura Biosciences, Inc. He served as a Director of X4 Pharmaceuticals Inc. Dr. Peters has served on the faculty/clinical staff at Harvard Medical School/Massachusetts General Hospital in Boston. He began his medical training at the Universit??? Catholique de Louvain in Brussels, Belgium. He has served as a consulting editor for JAMA and as a contributing editor for Science and has authored over 120 research articles and editorials. Dr. Peters earned his M.D. and Ph.D. in Pharmacology from the Medical University of South Carolina and a B.S. from the College of Charleston. He completed postgraduate training at Massachusetts General Hospital and a Howard Hughes Medical Institute Fellowship in biophysics at Harvard Medical School.

Merrimack Pharmaceuticals CEO Richard Peters At a Glance

The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at Merrimack Pharmaceuticals.

Based on 4 ratings, Richard Peters ranks right below Juno Therapeutics' CEO, Hans Bishop.

Overall, the CEO score has remained stable over the last 90 days.